Evangelos Giampazolias received his BSc in Chemistry (2009) and MSc in Clinical Biochemistry (2012) from the University of Athens in Greece. In 2012, he moved to Glasgow, UK, for his PhD at the Cancer Research UK (CRUK) Scotland Institute under the supervision of Professor Stephen Tait. During his PhD, he studied the signaling cascades that link cell death modalities regulated by mitochondria to cancer immunity. For this, he was awarded the Institute of Cancer Sciences Prize (2017) and the CRUK Pontecorvo Prize (2018). Evangelos subsequently joined the group of Professor Caetano Reis e Sousa at the Francis Crick Institute in London, UK, as a Postdoctoral Fellow to study how detection of dying tumour cells by receptors expressed on dendritic cells elicit immunity to cancer. He was granted an innovation patent (2020) to explore the therapeutic potential of his findings as novel immunotherapies for cancers. During the transition to his current independent position, Evangelos identified host-microbiome interactions that shape immune responses to extraintestinal tumours. In 2023, Evangelos funded by a CRUK Institute Award established the Cancer Immunosurveillance group at the CRUK Manchester Institute, which focuses on the characterisation of the mechanisms that enable the immune system to recognise and respond to cancer through integration of cues that are elicited by commensal microbes and damaged cells. In 2024, Evangelos was awarded an ERC Starting Grant to expand his latest discoveries and study the mechanisms that couple nutrient-host-microbiome interactions to cancer immunity.